• Vinod Kumar Pharm.D. Intern, Doctor of Pharmacy Program, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra
  • Bijoy Kumar Panda Asst. Professor, Doctor of Pharmacy Program, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra


Objectives: In Indian health-care system with delayed access to a minimum number of catheter laboratories and rarity of insurance benefits, prehospital
and in-hospital thrombolytic has become the choice for patients with acute coronary syndrome (ACS), where many patients bear the economic
burden of pharmacological thrombolytic. The present study was carried out to evaluate the pattern of prescribing of pharmacological thrombolytic
agents in hospitalized ACS patients and associated cost burden.
Methods: A prospective observational cohort study of prescription was conducted for in-patient admitted to intensive care unit for thrombolytic and
antithrombotic drug utilization pattern. The direct cost analysis was performed from patient's perspective where a direct cost was calculated using
pharmacy bills. All other cost was assumed to be same.
Results: Data of 288 patients were collected from which 108 (37.5%) patients were ST-elevation myocardial infarction (STEMI) and 180 (62.5%)
patients were non-STEMI. The mean number of drugs prescribed was 11±2 which constitutes a mean of 3.1±0.7 reperfusion drugs. 59% of patients
were prescribed with enoxaparin (0.6 ml/seconds route) for the mean duration of 4 days. The average prescription cost for ACS admission was around
Rs.7159.5±5137.2 (Rs.1101-Rs.22202). The average cost of pharmacological thrombolytic therapy was Rs.4557±3468.3 (Rs. 23-Rs.12542). The mean
cost of pharmacological thrombolytic therapy was found to be 63% of the total direct cost of drugs borne by the patient. The cost of therapy was
positively correlated with duration of stay (p=0.000) and insignificantly correlated with a number of drugs.
Conclusion: Antiplatelets were the most preferred followed by anticoagulants. The mean number of drugs per encounter was high but was rational
as per standard guidelines. The mean cost for pharmacological reperfusion therapy was found to be more than half of mean prescription cost for the
management of ACS.
Keywords: Acute coronary syndrome, Thrombolytic therapy, Cost, Medication management.


1. Liu Y, Dalal K. Review of cost-effectiveness analysis of medical treatment for myocardial infarction. Int J Prev Med 2011;2(2):64-72.
2. Gonzalez ER. Acute myocardial infarction. Textbook of Therapeutics: Drug and Disease Management. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 397.
3. Dalal J, Sahoo PK, Singh RK, Dhall A, Kapoor R, Krishnamurthy A, et al. Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario. Indian Heart J 2013;65(5):566-85.
4. Mardikar HM, Deshpande NV, Admane P. Recent advances in the management of acute myocardial infarction. J Assoc Physicians India 2011;59 Suppl:31-6.
5. Barron HV, Bowlby LJ, Breen T, Rogers WJ, Canto JG, Zhang Y, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. Circulation 1998;97(12):1150-6.
6. Al-Junid SM, Ezat WP, Surianti S. Prescribing pattern and drug cost among cardiovascular patients in Hospital University Kebangsaan Malaysia. Med J Malaysia 2007;62(1):59-65.
7. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study. Eur Heart J 2008;29(7):932-40.
8. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: The Framingham study. Ann Intern Med 1976;85(4):447-52.
9. Wal P, Wal A, Nair VR, Rai AK, Pandey U. Management of coronary artery disease in a tertiary care hospital. J Basic Clin Pharm 2013;4(2):31-5.
10. Saczynski JS, Lessard D, Spencer FA, Gurwitz JH, Gore JM, Yarzebski J, et al. Declining length of stay for patients hospitalized with AMI: Impact on mortality and readmissions. Am J Med 2010;123(11):1007-15.
11. Li Q, Lin Z, Masoudi FA, Li J, Li X, Hernández-Díaz S, et al. National trends in hospital length of stay for acute myocardial infarction in China. BMC Cardiovasc Disord 2015;15:9.
12. Shankar R, Partha P, Shenoy N. Prescribing patterns of drugs amongpatients admitted with cardiovascular disorders in the internal medicine ward: Prescribing patterns in inpatients. Int J Pharmacol 2001;1(2):1-5.
13. Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V, Padmakumar R. Potential drug interactions in patients admitted to cardiology wards of a South Indian teaching hospital. Australas Med J 2011;4(1):9-14.
14. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130(25):2354-94.
15. Christian RP, Rana DA, Malhotra SD, Patel VJ. Evaluation of rationality in prescribing, adherence to treatment guidelines, and direct cost of treatment in intensive cardiac care unit: A prospective observational study. Indian J Crit Care Med 2014;18(5):278-84.
16. Kumolosasi E, Wei WS, Wee CE. The use of thrombolytic agents in acute myocardial infarction (AMI) patients. Int J Pharm Pharm Sci 2013;7(3):183-5.
17. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction – a pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33(3):627-33.
18. Rubboli A. Efficacy and safety of low molecular weight heparin as adjuvant to thrombolysis in acute ST - Elevation myocardial infarction. Curr Cardiol Rev 2008;4(1):63-71.
19. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low molecular weight heparin as adjuncts to thrombolysis in aspirin - Treated patients with ST - Elevation acute myocardial infarction. Am Heart Assoc 2005;112(25):3855-67.
20. Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, et al. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009. p. 348.
21. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354(14):1477-88.
22. Marcoff L, Zhang Z, Zhang W, Ewen E, Jurkovitz C, Leguet P, et al. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction 25) study. J Am Coll Cardiol 2009;54(14):1271-9.
23. Alam S, Naqvi SB, Ahmed M. Drug utilization and economic impact of anticoagulants in unstable angina/non - ST elevation myocardial infarction in Karachi. Int J Pharm Pharm Sci 2015;7(3):183-5.
331 Views | 350 Downloads
How to Cite
Kumar, V., and B. K. Panda. “CAN COST OF PHARMACOLOGICAL THROMBOLYTIC THERAPY BE A MEDICATION MANAGEMENT STRATEGY FOR ACUTE CORONARY SYNDROME?”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 3, Mar. 2017, pp. 363-6, doi:10.22159/ajpcr.2017.v10i3.16308.
Original Article(s)